The Outcome of the Treatment of Malnourished Children Treated by Ready- To-Use Therapeutic Food and Ready to Use Supplementary Food in Wad- El- Bashir Heath Center, 2021
No Thumbnail Available
Date
2022-10-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
ERC
Abstract
Introduction: Malnutrition includes both undernutrition and overnutrition. Child undernutrition
is a major global health problem that is more common in low-income countries like Sudan, it can
cause childhood morbidity, mortality, and impaired intellectual development. Objective: This
study was conducted to assess the outcome of malnourished children treated with ready to-Use
Therapeutic Food (RUTF), and ready to-Use Supplementary Food (RUSF) in Wad Elbasheir
Health Centre in Ombada Locality Methods: This is an analytical Cross-Sectional facility-based
Study conducted at Wad Elbasheir Health Centre. A convenient nonprobability sampling
technique was used in this study. Data were collected using a datasheet after being pretested.
Data were collected from secondary data from the records of malnourished children treated by
the RTUF and RUSF. Results: The majority of the participants of this study were aged between
6 to 23 months (84%) and most of the participants were females (56%). This study showed that
70 (24%) of the participants were classified as severe Acute Malnutrition (SAM), while 218
(76%) were classified as moderate Acute malnutrition (MAM). This study showed that having a
smaller number of children in the family and middle Upper Arm Circumference (MUAC)
between 11.5-12.5 cm were more associated with recovery. Moreover, this study showed that
children who use amoxicillin or anti-worms were more likely to be recovered from malnutrition.
Conclusion: RUTF was designed for the nutritional management of children with uncomplicated
acute malnutrition treated as outpatients. In this study, most of the children recovered. In
addition, this study found that several factors were associated with better outcomes including
fewer children in the family, MUAC between 11.5-12.5 cm, having MAM (compared to having
SAM), and using amoxicillin or anti-worms.